Spyre Therapeutics Reports $69M Net Loss in Q1 2026, Increases R&D Spending

Spyre Therapeutics, Inc. reported a net loss of $69.0 million for the first quarter of 2026, a significant increase from the $44.8 million loss recorded in the same period of 2025. The company's total operating expenses decreased to $45.6 million from $53.6 million year-over-year, primarily due to a $30.0 million gain recognized from the sale of in-process research and development assets related to pegzilarginase. Research and development expenses rose by 45% to $60.4 million, driven by increased clinical trial and manufacturing costs, as well as higher compensation expenses.

The company’s cash and cash equivalents increased to $97.2 million as of March 31, 2026, up from $85.7 million at the end of 2025. However, total assets decreased to $763.9 million from $777.8 million, largely due to a reduction in marketable securities. Spyre's accumulated deficit reached $1.2 billion, reflecting the ongoing financial challenges typical of clinical-stage biotechnology firms. The company has raised approximately $1.7 billion since its inception, with recent financing activities including a public offering that generated net proceeds of approximately $435.3 million in April 2026.

In terms of strategic developments, Spyre Therapeutics has made significant progress in its clinical pipeline, which includes several monoclonal antibodies targeting inflammatory bowel disease (IBD) and rheumatic diseases. The company is advancing its SKYLINE Phase 2 platform trial, which evaluates multiple investigational agents, including SPY001, SPY002, and SPY003, in subjects with moderately to severely active ulcerative colitis. Initial topline data from the trial is expected in mid-2026, with ongoing enrollment in the trial's second part.

Operationally, Spyre has seen a notable increase in its research and development headcount, contributing to higher internal expenses. The company also reported a significant increase in external research and development costs, particularly in IBD and rheumatic diseases, reflecting its commitment to advancing its clinical programs. As of March 31, 2026, Spyre had approximately 78.8 million shares of common stock outstanding, up from 78.2 million at the end of 2025.

Looking ahead, Spyre Therapeutics anticipates continued investment in its clinical development programs, with plans to secure additional financing to support its research and development efforts. The company remains focused on its goal of developing next-generation therapeutics that could redefine the standard of care for IBD and other immune-mediated diseases. However, the company acknowledges the inherent risks and uncertainties associated with clinical development and the need for ongoing funding to sustain its operations.